Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing
Authors:
Open Access
- 19 November 2015
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (3) , 562-568
Abstract
Background: Paracetamol protein adducts (PPA) are a biomarker of paracetamol exposure. PPA are quantified as paracetamol–cysteine (APAP‐CYS), and concentrations above 1.1 μmol l–1 have been suggested as a marker of paracetamol‐induced hepatotoxicity. However, there is little information on the range of concentrations observed during prolonged therapeutic dosing.Aim: The aim of the present study was to describe the concentration of PPA in the serum of subjects taking therapeutic doses of paracetamol for at least 16 days.Methods: Preplanned secondary aim of a prospective randomized controlled (placebo vs. 4g day–1 paracetamol) trial. We measured subjects' serum PPA concentrations every 3 days for a minimum of 16 days. We also measured concentrations on study days 1–3 and 16–25 in subsets of patients. PPA were quantified as APAP‐CYS after gel filtration and protein digestion using liquid chromatography/mass spectrometry.RESULTS: Ninety per cent of subjects had detectable PPA after five doses. Median APAP‐CYS concentrations in paracetamol‐treated subjects increased to a plateau of 0.1 μmol l–1 on day 7, where they remained. The highest concentration measured was 1.1 μmol l–1 and two subjects never had detectable PPA levels. PPA were detected in the serum of 78% of subjects 9 days after their final dose.Conclusions: PPA are detectable in the vast majority of subjects taking therapeutic doses of paracetamol. While most have concentrations well below the threshold associated with hepatotoxicity, concentrations may approach 1.1 μmol l–1 in rare cases. Adducts are detectable after a few doses and can persist for over a week after dosing is stopped.Keywords
This publication has 16 references indexed in Scilit:
- Quantification of a biomarker of acetaminophen protein adducts in human serum by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Clinical and animal model applicationsJournal of Chromatography B, 2015
- Keratin‐18 and microRNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohortsLiver International, 2013
- HepaRG Cells: A Human Model to Study Mechanisms of Acetaminophen Hepatotoxicity ΔσHepatology, 2010
- Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failureHepatology, 2010
- Pharmacokinetics of Acetaminophen-Protein Adducts in Adults with Acetaminophen Overdose and Acute Liver FailureDrug Metabolism and Disposition, 2009
- Acetaminophen-Associated Hepatic Injury: Evaluation of Acetaminophen Protein Adducts in Children and Adolescents With Acetaminophen OverdoseClinical Pharmacology & Therapeutics, 2008
- Detection of Acetaminophen Protein Adducts in Children With Acute Liver Failure of Indeterminate CausePediatrics, 2006
- Measurement of Serum Acetaminophen–Protein Adducts in Patients With Acute Liver FailureGastroenterology, 2006
- Determination of Acetaminophen-Protein Adducts in Mouse Liver and Serum and Human Serum after Hepatotoxic Doses of Acetaminophen Using High-Performance Liquid Chromatography with Electrochemical DetectionDrug Metabolism and Disposition, 2002
- Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adultsClinical Pharmacology & Therapeutics, 2000